Global Intramuscular Injection of Pain Medication Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Intramuscular Injection of Pain Medication Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- 1.3.3 Opioid Analgesics (Opioids)
- 1.3.4 Local Anesthetics
- 1.3.5 Others
- 1.4 Market Analysis by Analgesic Potency
- 1.4.1 Overview: Global Intramuscular Injection of Pain Medication Consumption Value by Analgesic Potency: 2021 Versus 2025 Versus 2032
- 1.4.2 Medication for Mild-to-Moderate Pain
- 1.4.3 Medication for Moderate-to-Severe Pain
- 1.4.4 Medication for Severe Pain
- 1.5 Market Analysis by Duration of Analgesia
- 1.5.1 Overview: Global Intramuscular Injection of Pain Medication Consumption Value by Duration of Analgesia: 2021 Versus 2025 Versus 2032
- 1.5.2 <4 Hours
- 1.5.3 4–8 Hours
- 1.5.4 8 Hours
- 1.6 Market Analysis by Application
- 1.6.1 Overview: Global Intramuscular Injection of Pain Medication Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Hospitals (Emergency Care, Surgery, and Inpatient Pain Management)
- 1.6.3 Clinics (Outpatient Pain Treatment and Short-Term Procedures)
- 1.6.4 Others (Emergency Medical Services, Nursing Care, and Other Medical Settings)
- 1.7 Global Intramuscular Injection of Pain Medication Market Size & Forecast
- 1.7.1 Global Intramuscular Injection of Pain Medication Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global Intramuscular Injection of Pain Medication Sales Quantity (2021-2032)
- 1.7.3 Global Intramuscular Injection of Pain Medication Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Novartis
- 2.1.1 Novartis Details
- 2.1.2 Novartis Major Business
- 2.1.3 Novartis Intramuscular Injection of Pain Medication Product and Services
- 2.1.4 Novartis Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Novartis Recent Developments/Updates
- 2.2 Pfizer
- 2.2.1 Pfizer Details
- 2.2.2 Pfizer Major Business
- 2.2.3 Pfizer Intramuscular Injection of Pain Medication Product and Services
- 2.2.4 Pfizer Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Pfizer Recent Developments/Updates
- 2.3 Sanofi
- 2.3.1 Sanofi Details
- 2.3.2 Sanofi Major Business
- 2.3.3 Sanofi Intramuscular Injection of Pain Medication Product and Services
- 2.3.4 Sanofi Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Sanofi Recent Developments/Updates
- 2.4 Hengrui Medicine
- 2.4.1 Hengrui Medicine Details
- 2.4.2 Hengrui Medicine Major Business
- 2.4.3 Hengrui Medicine Intramuscular Injection of Pain Medication Product and Services
- 2.4.4 Hengrui Medicine Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Hengrui Medicine Recent Developments/Updates
- 2.5 Hikma Pharmaceuticals
- 2.5.1 Hikma Pharmaceuticals Details
- 2.5.2 Hikma Pharmaceuticals Major Business
- 2.5.3 Hikma Pharmaceuticals Intramuscular Injection of Pain Medication Product and Services
- 2.5.4 Hikma Pharmaceuticals Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Hikma Pharmaceuticals Recent Developments/Updates
- 2.6 Fresenius Kabi
- 2.6.1 Fresenius Kabi Details
- 2.6.2 Fresenius Kabi Major Business
- 2.6.3 Fresenius Kabi Intramuscular Injection of Pain Medication Product and Services
- 2.6.4 Fresenius Kabi Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 Fresenius Kabi Recent Developments/Updates
- 2.7 Baxter International Inc.
- 2.7.1 Baxter International Inc. Details
- 2.7.2 Baxter International Inc. Major Business
- 2.7.3 Baxter International Inc. Intramuscular Injection of Pain Medication Product and Services
- 2.7.4 Baxter International Inc. Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.7.5 Baxter International Inc. Recent Developments/Updates
- 2.8 Maruishi Pharmaceutical Co., Ltd.
- 2.8.1 Maruishi Pharmaceutical Co., Ltd. Details
- 2.8.2 Maruishi Pharmaceutical Co., Ltd. Major Business
- 2.8.3 Maruishi Pharmaceutical Co., Ltd. Intramuscular Injection of Pain Medication Product and Services
- 2.8.4 Maruishi Pharmaceutical Co., Ltd. Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.8.5 Maruishi Pharmaceutical Co., Ltd. Recent Developments/Updates
- 2.9 Ketorolac Tromethamine Injection
- 2.9.1 Ketorolac Tromethamine Injection Details
- 2.9.2 Ketorolac Tromethamine Injection Major Business
- 2.9.3 Ketorolac Tromethamine Injection Intramuscular Injection of Pain Medication Product and Services
- 2.9.4 Ketorolac Tromethamine Injection Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.9.5 Ketorolac Tromethamine Injection Recent Developments/Updates
- 2.10 Sun Pharmaceutical Industries Ltd.
- 2.10.1 Sun Pharmaceutical Industries Ltd. Details
- 2.10.2 Sun Pharmaceutical Industries Ltd. Major Business
- 2.10.3 Sun Pharmaceutical Industries Ltd. Intramuscular Injection of Pain Medication Product and Services
- 2.10.4 Sun Pharmaceutical Industries Ltd. Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.10.5 Sun Pharmaceutical Industries Ltd. Recent Developments/Updates
- 2.11 Humanwell Healthcare (Group) Co., Ltd.
- 2.11.1 Humanwell Healthcare (Group) Co., Ltd. Details
- 2.11.2 Humanwell Healthcare (Group) Co., Ltd. Major Business
- 2.11.3 Humanwell Healthcare (Group) Co., Ltd. Intramuscular Injection of Pain Medication Product and Services
- 2.11.4 Humanwell Healthcare (Group) Co., Ltd. Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.11.5 Humanwell Healthcare (Group) Co., Ltd. Recent Developments/Updates
- 2.12 Yangtze River Pharmaceutical Group
- 2.12.1 Yangtze River Pharmaceutical Group Details
- 2.12.2 Yangtze River Pharmaceutical Group Major Business
- 2.12.3 Yangtze River Pharmaceutical Group Intramuscular Injection of Pain Medication Product and Services
- 2.12.4 Yangtze River Pharmaceutical Group Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.12.5 Yangtze River Pharmaceutical Group Recent Developments/Updates
- 2.13 KRKA, d. d.
- 2.13.1 KRKA, d. d. Details
- 2.13.2 KRKA, d. d. Major Business
- 2.13.3 KRKA, d. d. Intramuscular Injection of Pain Medication Product and Services
- 2.13.4 KRKA, d. d. Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.13.5 KRKA, d. d. Recent Developments/Updates
- 2.14 Medochemie Ltd.
- 2.14.1 Medochemie Ltd. Details
- 2.14.2 Medochemie Ltd. Major Business
- 2.14.3 Medochemie Ltd. Intramuscular Injection of Pain Medication Product and Services
- 2.14.4 Medochemie Ltd. Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.14.5 Medochemie Ltd. Recent Developments/Updates
- 2.15 Polpharma S.A.
- 2.15.1 Polpharma S.A. Details
- 2.15.2 Polpharma S.A. Major Business
- 2.15.3 Polpharma S.A. Intramuscular Injection of Pain Medication Product and Services
- 2.15.4 Polpharma S.A. Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.15.5 Polpharma S.A. Recent Developments/Updates
- 2.16 Gland Pharma Limited
- 2.16.1 Gland Pharma Limited Details
- 2.16.2 Gland Pharma Limited Major Business
- 2.16.3 Gland Pharma Limited Intramuscular Injection of Pain Medication Product and Services
- 2.16.4 Gland Pharma Limited Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.16.5 Gland Pharma Limited Recent Developments/Updates
- 2.17 Sopharma AD
- 2.17.1 Sopharma AD Details
- 2.17.2 Sopharma AD Major Business
- 2.17.3 Sopharma AD Intramuscular Injection of Pain Medication Product and Services
- 2.17.4 Sopharma AD Intramuscular Injection of Pain Medication Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.17.5 Sopharma AD Recent Developments/Updates
3 Competitive Environment: Intramuscular Injection of Pain Medication by Manufacturer
- 3.1 Global Intramuscular Injection of Pain Medication Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Intramuscular Injection of Pain Medication Revenue by Manufacturer (2021-2026)
- 3.3 Global Intramuscular Injection of Pain Medication Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Intramuscular Injection of Pain Medication by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Intramuscular Injection of Pain Medication Manufacturer Market Share in 2025
- 3.4.3 Top 6 Intramuscular Injection of Pain Medication Manufacturer Market Share in 2025
- 3.5 Intramuscular Injection of Pain Medication Market: Overall Company Footprint Analysis
- 3.5.1 Intramuscular Injection of Pain Medication Market: Region Footprint
- 3.5.2 Intramuscular Injection of Pain Medication Market: Company Product Type Footprint
- 3.5.3 Intramuscular Injection of Pain Medication Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Intramuscular Injection of Pain Medication Market Size by Region
- 4.1.1 Global Intramuscular Injection of Pain Medication Sales Quantity by Region (2021-2032)
- 4.1.2 Global Intramuscular Injection of Pain Medication Consumption Value by Region (2021-2032)
- 4.1.3 Global Intramuscular Injection of Pain Medication Average Price by Region (2021-2032)
- 4.2 North America Intramuscular Injection of Pain Medication Consumption Value (2021-2032)
- 4.3 Europe Intramuscular Injection of Pain Medication Consumption Value (2021-2032)
- 4.4 Asia-Pacific Intramuscular Injection of Pain Medication Consumption Value (2021-2032)
- 4.5 South America Intramuscular Injection of Pain Medication Consumption Value (2021-2032)
- 4.6 Middle East & Africa Intramuscular Injection of Pain Medication Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Intramuscular Injection of Pain Medication Sales Quantity by Type (2021-2032)
- 5.2 Global Intramuscular Injection of Pain Medication Consumption Value by Type (2021-2032)
- 5.3 Global Intramuscular Injection of Pain Medication Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Intramuscular Injection of Pain Medication Sales Quantity by Application (2021-2032)
- 6.2 Global Intramuscular Injection of Pain Medication Consumption Value by Application (2021-2032)
- 6.3 Global Intramuscular Injection of Pain Medication Average Price by Application (2021-2032)
7 North America
- 7.1 North America Intramuscular Injection of Pain Medication Sales Quantity by Type (2021-2032)
- 7.2 North America Intramuscular Injection of Pain Medication Sales Quantity by Application (2021-2032)
- 7.3 North America Intramuscular Injection of Pain Medication Market Size by Country
- 7.3.1 North America Intramuscular Injection of Pain Medication Sales Quantity by Country (2021-2032)
- 7.3.2 North America Intramuscular Injection of Pain Medication Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Intramuscular Injection of Pain Medication Sales Quantity by Type (2021-2032)
- 8.2 Europe Intramuscular Injection of Pain Medication Sales Quantity by Application (2021-2032)
- 8.3 Europe Intramuscular Injection of Pain Medication Market Size by Country
- 8.3.1 Europe Intramuscular Injection of Pain Medication Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Intramuscular Injection of Pain Medication Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Intramuscular Injection of Pain Medication Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Intramuscular Injection of Pain Medication Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Intramuscular Injection of Pain Medication Market Size by Region
- 9.3.1 Asia-Pacific Intramuscular Injection of Pain Medication Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Intramuscular Injection of Pain Medication Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Intramuscular Injection of Pain Medication Sales Quantity by Type (2021-2032)
- 10.2 South America Intramuscular Injection of Pain Medication Sales Quantity by Application (2021-2032)
- 10.3 South America Intramuscular Injection of Pain Medication Market Size by Country
- 10.3.1 South America Intramuscular Injection of Pain Medication Sales Quantity by Country (2021-2032)
- 10.3.2 South America Intramuscular Injection of Pain Medication Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Intramuscular Injection of Pain Medication Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Intramuscular Injection of Pain Medication Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Intramuscular Injection of Pain Medication Market Size by Country
- 11.3.1 Middle East & Africa Intramuscular Injection of Pain Medication Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Intramuscular Injection of Pain Medication Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Intramuscular Injection of Pain Medication Market Drivers
- 12.2 Intramuscular Injection of Pain Medication Market Restraints
- 12.3 Intramuscular Injection of Pain Medication Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Intramuscular Injection of Pain Medication and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Intramuscular Injection of Pain Medication
- 13.3 Intramuscular Injection of Pain Medication Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Intramuscular Injection of Pain Medication Typical Distributors
- 14.3 Intramuscular Injection of Pain Medication Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
According to our (Global Info Research) latest study, the global Intramuscular Injection of Pain Medication market size was valued at US$ 2212 million in 2025 and is forecast to a readjusted size of US$ 3274 million by 2032 with a CAGR of 6.1% during review period.
In 2025, the global production of intramuscular injection of pain medication reached approximately 768 million units, with an average global market price of around US$2.8 per unit. In the same year, the global total production capacity of intramuscular injection of pain medication reached 960 million units. The industry average gross profit margin of this product reached 47%.
Intramuscular analgesics are drugs and preparations administered via intramuscular injection to relieve moderate to severe pain or acute pain requiring rapid onset of action. After injection into muscle tissue, the drugs are absorbed into the systemic circulation through the rich local capillary network. Compared to some oral preparations, they typically have a faster onset of action, avoid gastrointestinal absorption instability, and are suitable for patients who cannot take oral medication. Based on their pharmacological mechanisms, intramuscular analgesics can include nonsteroidal anti-inflammatory drugs (NSAIDs), opioid analgesics, and some centrally acting drugs or compound preparations with analgesic effects. Specific varieties vary depending on national drug registration, clinical guidelines, and prescription management regulations. These products are mainly used for perioperative pain, traumatic pain, acute musculoskeletal pain, renal colic, and other clinical scenarios requiring short-term rapid analgesia. The selection and administration of these drugs are usually determined by healthcare professionals based on the degree of pain, the patient's underlying condition, and the risks associated with medication. Special attention must be paid to the safety risks associated with different categories of drugs, including gastrointestinal, renal, cardiovascular, respiratory depression, and dependence.
The upstream of the intramuscular injection analgesic drug industry chain mainly includes chemical raw materials, pharmaceutical excipients, water for injection, and pharmaceutical packaging materials. Among them, raw materials involve the corresponding analgesic active ingredients and their key intermediates, excipients include buffers, solubilizers, stabilizers, antioxidants, etc., and the packaging stage mainly uses pharmaceutical packaging products such as ampoules, vials, pre-filled syringes, rubber stoppers, and aluminum caps. The midstream consists of raw material manufacturers and injectable drug manufacturers. The core links cover raw material synthesis and purification, formulation development, aseptic preparation, filtration, filling, sterilization or aseptic production, quality testing, stability studies, and drug registration applications, which have high requirements for GMP management, aseptic production environment, and quality control system. The downstream is mainly used in hospitals, emergency centers, surgical centers, primary healthcare institutions, pain clinics, orthopedic departments, and other medical terminals, and is distributed by pharmaceutical commercial companies, professional drug distribution companies, and hospital pharmacies. Because some potent analgesics are strictly regulated or prescription drugs, their production, distribution, inventory, and clinical use are subject to rigorous supervision. Therefore, supply chain stability, product compliance, hospital access, centralized procurement, and coverage of clinical guidelines are crucial factors influencing a company's market competitiveness.
The overall market for intramuscular analgesics is expected to maintain relatively stable clinical demand in the future, primarily driven by increased global surgical volume, a growing number of trauma and emergency patients, an aging population, and improved standardized management of perioperative and acute pain. At the same time, industry development is not simply reliant on increased use of traditional potent analgesics, but is gradually evolving towards safer, more precise, and multimodal analgesia. Clinical practice increasingly emphasizes stratified medication based on pain intensity and patient risk, and reduces unnecessary opioid exposure through NSAIDs, local anesthetics, and other non-opioid analgesic regimens. Therefore, injectable analgesics with rapid onset of action, stable efficacy, lower risk of gastrointestinal or central nervous system adverse reactions, and high ease of administration are expected to have significant growth potential. Prefilled formulations, unit-dose packaging, and products suitable for day surgery and rapid analgesia in emergency situations are also likely to see wider adoption. However, this market is also affected by factors such as consistency evaluation of injectable drugs, price competition of generic drugs, centralized procurement, strict regulation of opioids, and substitution of oral, intravenous, transdermal and local administration methods. In the future, the focus of competition among companies will be more on product safety, differentiated indications, formulation technology, cost control and hospital terminal coverage.
Report Scope
This report is a detailed and comprehensive analysis for global Intramuscular Injection of Pain Medication market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Intramuscular Injection of Pain Medication market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Intramuscular Injection of Pain Medication market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Intramuscular Injection of Pain Medication market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Intramuscular Injection of Pain Medication market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Intramuscular Injection of Pain Medication
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Intramuscular Injection of Pain Medication market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Pfizer, Sanofi, Hengrui Medicine, Hikma Pharmaceuticals, Fresenius Kabi, Baxter International Inc., Maruishi Pharmaceutical Co., Ltd., Ketorolac Tromethamine Injection, Sun Pharmaceutical Industries Ltd., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Intramuscular Injection of Pain Medication market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market Segmentation
Market segment by Type
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Opioid Analgesics (Opioids)
Local Anesthetics
Others
Market segment by Analgesic Potency
Medication for Mild-to-Moderate Pain
Medication for Moderate-to-Severe Pain
Medication for Severe Pain
Market segment by Duration of Analgesia
<4 Hours
4–8 Hours
8 Hours
Market segment by Application
Hospitals (Emergency Care, Surgery, and Inpatient Pain Management)
Clinics (Outpatient Pain Treatment and Short-Term Procedures)
Others (Emergency Medical Services, Nursing Care, and Other Medical Settings)
Major players covered
Novartis
Pfizer
Sanofi
Hengrui Medicine
Hikma Pharmaceuticals
Fresenius Kabi
Baxter International Inc.
Maruishi Pharmaceutical Co., Ltd.
Ketorolac Tromethamine Injection
Sun Pharmaceutical Industries Ltd.
Humanwell Healthcare (Group) Co., Ltd.
Yangtze River Pharmaceutical Group
KRKA, d. d.
Medochemie Ltd.
Polpharma S.A.
Gland Pharma Limited
Sopharma AD
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Intramuscular Injection of Pain Medication product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Intramuscular Injection of Pain Medication, with price, sales quantity, revenue, and global market share of Intramuscular Injection of Pain Medication from 2021 to 2026.
Chapter 3, the Intramuscular Injection of Pain Medication competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Intramuscular Injection of Pain Medication breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Intramuscular Injection of Pain Medication market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Intramuscular Injection of Pain Medication.
Chapter 14 and 15, to describe Intramuscular Injection of Pain Medication sales channel, distributors, customers, research findings and conclusion.